The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab
MS Treatments
Jahr
Publikationsjahr
2024
Autoren
Autorenliste der Publikation
Hersh CM, Pang M, Miller DM, McGinley MP, Hyland M, Ziemssen T, Avila RL.
Verlag
Publisher-Information
Neurodegener Dis Manag. 2024 Apr 16.
Link
Zur Publikation (externer Server)
https://doi.org/10.2217/nmt-2023-0047
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
MSZ
Treatments
2024
MS brain health quality standards: a survey on the reality in clinical practice in Germany
Multiple Sclerosis
Jahr
2024
Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study
MS Treatments
Jahr
2024
Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study
Multiple Sclerosis
Jahr
2024
Eculizumab Use in Neuromyelitis Optica Spectrum Disorders
MS Treatments
Jahr
2024
Higher effect sizes for the detection of accelerated brain volume loss and disability progression in multiple sclerosis using deep-learning
MASC
Jahr
2024
